These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 27496669)

  • 1. Risks of inhibitors from recombinant factor VIII: a quarter of a century to reach the conclusion.
    Burnouf T; Strengers PF
    J Thromb Haemost; 2016 Oct; 14(10):2073-2074. PubMed ID: 27496669
    [No Abstract]   [Full Text] [Related]  

  • 2. Low-titre inhibitors, undetectable by the Nijmegen assay, reduce factor VIII half-life after immune tolerance induction.
    Dardikh M; Albert T; Masereeuw R; Oldenburg J; Novakova I; van Heerde WL; Verbruggen B
    J Thromb Haemost; 2012 Apr; 10(4):706-8. PubMed ID: 22284849
    [No Abstract]   [Full Text] [Related]  

  • 3. Exposure to factor VIII and prediction of inhibitor development: exposure days vs. danger days, or both?
    Hermans C; Astermark J; De Moerloose P
    J Thromb Haemost; 2012 Oct; 10(10):2194-6. PubMed ID: 22846047
    [No Abstract]   [Full Text] [Related]  

  • 4. Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review.
    Franchini M; Lippi G
    Thromb Haemost; 2010 Nov; 104(5):931-40. PubMed ID: 20838738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocytic receptor for pro-coagulant factor VIII: relevance to inhibitor formation.
    Navarrete AM; Dasgupta S; Teyssandier M; Repesse Y; Delignat S; André S; Bayry J; Kaveri SV; Lacroix-Desmazes S
    Thromb Haemost; 2010 Dec; 104(6):1093-8. PubMed ID: 20886186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of factor VIII inhibitors in patients with hemophilia A in Brazil.
    Rieger A; Roisenberg I
    Thromb Haemost; 1999 Mar; 81(3):475-6. PubMed ID: 10102489
    [No Abstract]   [Full Text] [Related]  

  • 7. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review.
    Hassan S; Cannavò A; Gouw SC; Rosendaal FR; van der Bom JG
    J Thromb Haemost; 2018 Jun; 16(6):1055-1068. PubMed ID: 29665204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term secondary prophylaxis with recombinant activated factor VII (rFVIIa) in haemophilia A with inhibitors: a case report.
    Kubisz P; Plamenová I; Stasko J; Dobrotová M; Hollý P
    Thromb Haemost; 2010 Apr; 103(4):868-70. PubMed ID: 20135075
    [No Abstract]   [Full Text] [Related]  

  • 9. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.
    Peyvandi F; Cannavò A; Garagiola I; Palla R; Mannucci PM; Rosendaal FR;
    J Thromb Haemost; 2018 Jan; 16(1):39-43. PubMed ID: 29080391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor VIII inhibitors in previously treated hemophilic patients.
    Mannucci PM
    J Thromb Haemost; 2011 Nov; 9(11):2328-9. PubMed ID: 21929691
    [No Abstract]   [Full Text] [Related]  

  • 11. Searching for the role of primary prophylaxis in preventing inhibitor development in hemophilia A.
    Coppola A; Tagliaferri A; Franchini M
    J Thromb Haemost; 2012 Sep; 10(9):1954-60. PubMed ID: 22758924
    [No Abstract]   [Full Text] [Related]  

  • 12. Porcine factor VIII.
    Giangrande PL
    Haemophilia; 2012 May; 18(3):305-9. PubMed ID: 22531020
    [No Abstract]   [Full Text] [Related]  

  • 13. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A.
    Mancuso ME; Mannucci PM; Rocino A; Garagiola I; Tagliaferri A; Santagostino E
    J Thromb Haemost; 2012 May; 10(5):781-90. PubMed ID: 22452823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-A2 and anti-A1 domain antibodies are potential predictors of immune tolerance induction outcome in children with hemophilia A.
    Lapalud P; Rothschild C; Mathieu-Dupas E; Balicchi J; Gruel Y; Laune D; Molina F; Schved JF; Granier C; Lavigne-Lissalde G
    J Thromb Haemost; 2015 Apr; 13(4):540-7. PubMed ID: 25603934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Best evidence on B-domain deletion and the immunogenicity of recombinant factor VIII.
    Aledort LM; Navickis RJ; Wilkes MM
    J Thromb Haemost; 2011 Nov; 9(11):2325-7. PubMed ID: 21880112
    [No Abstract]   [Full Text] [Related]  

  • 16. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
    Young G; Mahlangu J; Kulkarni R; Nolan B; Liesner R; Pasi J; Barnes C; Neelakantan S; Gambino G; Cristiano LM; Pierce GF; Allen G
    J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitor development in non-severe haemophilia across Europe.
    Fischer K; Iorio A; Lassila R; Peyvandi F; Calizzani G; Gatt A; Lambert T; Windyga J; Gilman EA; Hollingsworth R; Makris M;
    Thromb Haemost; 2015 Oct; 114(4):670-5. PubMed ID: 26293381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.
    Zakas PM; Vanijcharoenkarn K; Markovitz RC; Meeks SL; Doering CB
    J Thromb Haemost; 2015 Jan; 13(1):72-81. PubMed ID: 25315236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term tolerance to factor VIII is achieved by administration of interleukin-2/interleukin-2 monoclonal antibody complexes and low dosages of factor VIII.
    Liu CL; Ye P; Lin J; Djukovic D; Miao CH
    J Thromb Haemost; 2014 Jun; 12(6):921-31. PubMed ID: 24684505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
    Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
    Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.